Here is an update on recent en banc activity at the Federal Circuit in patent cases. Highlights include two new petitions raising questions related to waiver of the prevailing arguments made in Arthrex, Inc. v. Smith & Nephew, Inc., non-obviousness, and argument-type prosecution history estoppel, two letters filed by the government in response to arguments related to Arthrex, Inc. v. Smith & Nephew, Inc., two amicus briefs in Arthrex, Inc. v. Smith & Nephew, Inc. itself, and the denial of four petitions. We have the details.
Last week the Federal Circuit heard oral arguments during its September sitting in Washington DC. Here is a short recap of Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals Inc., one of the argued cases we’re following.